The discount is the second lever on a SAFE — alongside the cap — that rewards early investors with a cheaper per-share price at conversion. It is simple until you pair it with a cap and forget which one wins.
Reading time: 7 minutes. Worked example at $2/share with cap crossover. Numbers you can verify in a spreadsheet.
The discount rate on a SAFE gives the investor a reduced per-share price when the SAFE converts at the next priced equity round. If the Series A price is $2.00/share and the SAFE carries a 20% discount, the conversion price is $1.60/share — not because the company is worth less, but because the early investor took risk before anyone agreed on a number.
Discounts of 10–20% are standard in US seed practice. European party rounds often land at 15–20% for the first €250k–€500k in, then taper for later angels. A discount without a cap is a modest "thank you for being early" — it only bites if the company raises flat or down.
Discounts do not stack with caps. Standard YC SAFEs give the investor the better of cap or discount — meaning whichever produces the lower conversion price and therefore more shares. Not both.
Discount path: conversion price = round price × (1 − discount). Shares issued = SAFE amount ÷ conversion price.
Cap path: implied price = cap ÷ fully diluted shares at conversion (post-money SAFEs use the post-money cap directly as the ownership fraction). Shares issued = SAFE amount ÷ that implied price.
The investor (and the SAFE document) picks whichever path yields the lower price. In a strong up-round, the cap usually dominates — the discount sits unused but still costs you negotiating leverage. In a flat round, the discount can be the better deal for the investor even with a cap on the document.
Founders sometimes offer discount-only SAFEs on small €25k–€50k checks to avoid fixing a cap too early. Investors accept when they are betting on a large up-round where the cap would matter more than 15% off. Know which scenario you are actually in.
An investor puts $200,000 into a SAFE with a 20% discount and a $5M post-money cap. You later raise Series A at $2.00/share on a $20M post-money valuation.
Discount path: conversion price = $2.00 × (1 − 0.20) = $1.60/share. Shares = $200,000 ÷ $1.60 = 125,000 shares. At the round price, that stake is worth $250,000 on paper — a 1.25× markup before the new money even lands.
Cap path (post-money): ownership = $200k ÷ $5M = 4% of the company at conversion. If the round implies 10M shares outstanding post-money at $2.00 ($20M), 4% = 400,000 shares — equivalent to a $0.50/share conversion price for this investor.
The cap wins easily in an up-round. The discount mattered in negotiation; the cap did the work. Run both paths every time — founders who only model the discount wake up at conversion wondering why the investor owns twice what they expected.
€50k angel on 20% discount, no cap: you are betting on an up-round where a cap would hurt you. €500k lead on €8M cap, no discount: common at seed. Mismatching check size to structure signals you have not thought it through.
Model the cap path first. The discount is a floor for flat/down scenarios. If the cap math already gives away more than you can stomach, lowering the discount does not fix it.
Standard SAFEs: better of cap or discount. Bespoke docs sometimes stack them — cap price minus another 20%. That is a high-severity term; push back or price it into the cap.
Many seed founders cap discounts at 15–20% and refuse MFN-linked discount upgrades. Write it down once, enforce it consistently — party rounds punish ad-hoc concessions.
Upload the SAFE. Prism pulls the stated discount rate, whether a cap is present, and the "better of cap or discount" (or non-standard stacking) language. It compares the discount to your playbook maximum and runs the cap-vs-discount crossover against scenario round prices you care about (flat, base, up).
Output: categorised findings, market context for seed terms in your sector, and redlines ready to send. If your playbook says "max 15% discount" and the doc says 25% with MFN, that is flagged before you paste the DocuSign link into Slack.
V1 scope: extraction, playbook rules, findings, and redlines on the document you upload — not portfolio modelling across multiple SAFEs (do that in your cap table), but the single-doc review founders actually need at signing time.
Closed alpha. Premium tier — €49/month, no free tier, no demos. Read the home page if you haven't, then drop your email.
Valuation cap, in plain English — the single number that decides how much of the company you keep when the SAFE converts.
How a SAFE converts to equity — where cap and discount actually turn into shares at the priced round.
Post-money vs pre-money SAFE — why the 2018 post-money default quietly costs you more dilution when stacking SAFEs.
If there's a term you're trying to understand right now and it's not here, tell us — the order we write these in is driven by what founders ask for.
